Contact Us
Drug Search Results
More Filters [+]

Liafensine

Alternative Names: liafensine, bms-820836, bms820836, bms 820836, DB-104, DB104, DB 104
Latest Update: 2024-10-09
Latest Update Note: News Article

Product Description

Bristol-Myers Squibb is developing Liafensine as a treatment for Treatment Resistant Depression. (Sourced from: https://www.clinicaltrials.gov/study/NCT05113771)

Mechanisms of Action: NRI,SRI,DRI

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Depressive Disorder, Treatment-Resistant *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Liafensine

Countries in Clinic: Canada, China, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Depressive Disorder, Treatment-Resistant

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ENLIGHTEN

P2

Completed

Depressive Disorder, Treatment-Resistant

2024-02-06

CTR20221896

P2

Not yet recruiting

Depressive Disorder, Treatment-Resistant

None

Recent News Events

Date

Type

Title

10/09/2024

News Article

 FDA Grants Fast Track Designation For Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD)

05/28/2024

News Article

 Denovo Biopharma LLC to Present Positive Phase 2b ENLIGHTEN Trial Data for DGM4 Biomarker-Guided DB104 (liafensine) Treatment for Treatment ‑Resistant Depression at the ASCP 2024 Annual Meeting

05/01/2024

News Article

 Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant

04/30/2024

News Article

 CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

04/01/2024

PubMed

 Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression.

04/01/2024

PubMed

 Tagging the tjp1a Gene in Zebrafish with Monomeric Red Fluorescent Protein Using Biotin Homology Arms.

02/22/2024

PubMed

 Establishment and characterization of turtle liver organoids provides a potential model to decode their unique adaptations.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions